News
VIR
8.82
+0.63%
0.06
What Vir Biotechnology (VIR)'s Profit Swing But Earnings Miss Means For Shareholders
Simply Wall St · 1d ago
Vir Biotechnology (VIR) Could Be 58% Below Fair Value On Q2 Profit Turnaround
Simply Wall St · 3d ago
Vir Biotechnology price target lowered to $25 from $27 at Morgan Stanley
TipRanks · 3d ago
Vir Biotechnology price target lowered to $19 from $21 at Leerink
TipRanks · 3d ago
Analyst Reiterates Buy on Vir Biotechnology, Citing Advancing Hepatitis D and Oncology Pipelines and Strong Cash Runway
TipRanks · 3d ago
Vir Biotechnology (VIR) Gets a Buy from Barclays
TipRanks · 3d ago
*Vir Biotechnology 2Q EPS 47c >VIR
Dow Jones · 4d ago
*Vir Biotechnology 2Q Rev $238.9M >VIR
Dow Jones · 4d ago
Press Release: Vir Biotechnology Provides -2-
Dow Jones · 4d ago
Press Release: Vir Biotechnology Provides -3-
Dow Jones · 4d ago
Press Release: Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2026 Financial Results
Dow Jones · 4d ago
*Vir Biotechnology 2Q Net $80.1M >VIR
Dow Jones · 4d ago
Vir Biotechnology: Can the Pipeline Actually Replace What the Partnership Revenue Isn't Delivering
Barchart · 5d ago
Weekly Report: what happened at VIR last week (0727-0731)?
Weekly Report · 6d ago
Weekly Report: what happened at VIR last week (0720-0724)?
Weekly Report · 07/27 10:22
Vir Biotechnology Names Brent Sabatini Interim Finance Chief
TipRanks · 07/24 12:57
Vir Biotechnology Financial Chief to Depart
Dow Jones · 07/24 12:48
Vir Biotechnology announces Chief Financial Officer transition
Seeking Alpha · 07/24 12:39
Vir Biotechnology CFO Jason O’Byrne to depart
TipRanks · 07/24 12:35
More
Webull provides a variety of real-time VIR stock news. You can receive the latest news about Vir Biotechnology, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About VIR
Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing medicines for serious infectious diseases and cancer. Its portfolio includes programs for chronic hepatitis delta and multiple dual-masked T-cell engagers (TCEs) across validated targets in solid tumor indications. It also has a portfolio of preclinical programs across a range of infectious diseases and oncologic malignancies. Its key product candidates include Elebsiran (VIR-2218); Tobevibart (VIR-3434); VIR-5818; VIR-5525, and VIR-5500. These molecules leverage the PRO-XTEN masking technology with TCEs targeting CD3 on T-cells and HER2, PSMA and EGFR, respectively, on tumor cells. Elebsiran is an investigational hepatitis B virus (HBV)-targeted small interfering RNA that reduces hepatitis B surface antigen (HBsAg). Tobevibart is an investigational neutralizing monoclonal antibody that has been engineered for immune engagement and targets a conserved region on the HBsAg.